The Australian veterinary medicine vaccines market fell to $326M in 2024, which is down by -5.8% against the previous year. In general, consumption, however, posted a resilient increase. Veterinary medicine vaccines consumption peaked at $349M in 2021; however, from 2022 to 2024, consumption failed to regain momentum.

This dataset provides values for CORONAVIRUS VACCINATION RATE reported in several countries. The data includes current values, previous releases, historical highs and record lows, release frequency, reported unit and currency.

In 2024, the Australian vaccine market decreased by -99.7% to $7.6M, falling for the second consecutive year after three years of growth. Overall, consumption saw a sharp downturn. Over the period under review, the market reached the maximum level at $3.5B in 2022; however, from 2023 to 2024, consumption remained at a lower figure.

The paediatric vaccine market valuation is US$ 54,130.1 million in 2023. The market is predicted to grow at a remarkable CAGR of 13.1% to reach a valuation of US$ 184,706.7 million by 2033. Thus, it showcases that the paediatric vaccine market is due for significant growth over the coming years.

Attributes	Details
Paediatric Vaccine Market Value for 2023	US$ 54,130.1 million
Projected Market Value for 2033	US$ 184,706.7 million
Value-based CAGR for 2023 to 2033	13.1%

Historical Performance Compared to Demand Outlook in Paediatric Vaccine Market

Historical CAGR	9.7%
Forecast CAGR	13.1%

Category-wise Outlook

Attributes	Details
Top Indication	Pneumococcal Vaccine
Market Share in 2022	32.5%

Attributes	Details
Top Technology	Conjugate Vaccines
Market Share in 2022	32.8%

Attributes	Details
Top Type	Monovalent Vaccine
Market Share in 2022	73.6%

Attributes	Details
Top End-use Sector	Institutional health centers
Market Share in 2022	72.9%

Country-Wise Analysis

Countries	Market Share in 2022
United States	17.9%
China	19.6%
India	19.2%
United Kingdom	16.1%
Australia	9.4%

Vaccine exports dropped significantly to X tons in 2024, declining by X% compared with the year before. Over the period under review, exports continue to indicate a abrupt decrease. The growth pace was the most rapid in 2020 when exports increased by X% against the previous year. The volume of export peaked at X tons in 2013; however, from 2014 to 2024, the exports stood at a somewhat lower figure.

APAC Veterinary Vaccine Market size was valued to be USD 7.6 Billion in the year 2024 and it is expected to reach USD 13 Billion in 2032, at a CAGR of 7% from 2026 to 2032.

Key Market Drivers

Rising Livestock Population and Disease Prevention: Vaccine demand is driven by rising livestock populations and disease prevention concerns. According to the FAO, the APAC livestock population has increased by 34% since 2021, with 72% of commercial farms undertaking regular vaccination programs. According to studies, 85% of large-scale farms in China, India, and Australia have boosted vaccine investment by 45% to avoid economic losses caused by diseases.

Pet Ownership Growth: Pet ownership is on the rise, as are immunization rates. According to research, pet ownership in APAC urban areas has surged by 58% since 2020, with 82% of owners adhering to prescribed immunization schedules. In Japan and South Korea, pet vaccination compliance rates reached 91% by 2023, resulting in a 47% rise in companion animal vaccine sales.

Zoonotic Disease Prevention: Concerns about zoonotic disease transmission are driving vaccination use. According to WHO statistics, 75% of developing infectious illnesses in APAC are zoonotic, which has resulted in a 63% rise in preventive vaccination efforts. According to government data, 88% of commercial poultry farms currently require regular vaccination against avian influenza.

The veterinary medicine vaccines market in Australia and Oceania contracted modestly to $374M in 2024, declining by -3.5% against the previous year. In general, consumption continues to indicate a buoyant increase. Over the period under review, the market attained the peak level at $390M in 2021; however, from 2022 to 2024, consumption failed to regain momentum.

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck’s Gardasil, with GlaxoSmithKline’s (GSK’s) HPV vaccine Cervarix providing the only competition. The introduction of Merck’s nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector. In 2006 Gardasil (marketed as Silgard in Germany) became the first vaccine approved for prophylactic protection against HPV infection. Gardasil was primarily developed and marketed by Merck, under license from Australian biotechnology company CSL, which markets the vaccine in Australia and New Zealand. Gardasil is a quadrivalent vaccine containing recombinant virus-like particles (VLPs) of the L1 capsid protein from the HPV strains 6, 11, 16 and 18, combined with an aluminum adjuvant (amorphous aluminum hydroxyphosphate sulfatez Read More

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Menveo (Meningococcal groups A, C, Y, W-135 oligosaccharide diphtheria CRM197 conjugate vaccine) is Novartis’ tetravalent conjugate vaccine licensed in the US, EU, Australia, and Brazil to protect against four serogroups of N. meningitidis (A, C, Y, W-135) that cause meningococcal disease in children, adolescents, and adults. Approved in 2010 for all markets in this report, Menveo was the second tetravalent conjugate vaccine to enter the market in US and Australia and the first to enter the 5EU markets. Read More

Snapshot img

Syringe And Needle Market Size 2024-2028

The syringe and needle market size is forecast to increase by USD 10.96 billion at a CAGR of 8% between 2023 and 2028.

The market encompasses various types of syringes, including ophthalmic, bone marrow, and catheter syringes, which find applications in general surgery, diagnostic, and respiratory applications within the healthcare system. Market growth is driven by the increasing prevalence of critical care conditions and innovations in pre-filled syringes. However, competition from alternative drug delivery systems poses a challenge to market growth. Disposable syringes dominate the market due to their convenience and ease of use, while reusable syringes continue to be used in specific applications, such as orthopedic surgeries. The healthcare products industry is continually evolving, with a focus on improving patient safety and reducing healthcare costs. This market analysis report provides an in-depth examination of these trends and challenges in the market.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market holds a pivotal role in the healthcare industry, particularly in the context of drug delivery technology. This market caters to the requirements of hospitals and healthcare systems for various applications, including pre-filled syringes (PFS) for vaccinations and chronic therapies. Vaccinations are a crucial aspect of preventive healthcare, especially in the face of infectious diseases and long-term conditions such as diabetes, cardiovascular diseases, and cancer. The World Health Organization (WHO) focuses on the importance of vaccines in disease prevention and control and the need for a reliable and efficient market to ensure the availability of vaccine doses. The market also plays a significant role in the delivery of injectable drugs for chronic diseases like diabetes. Moreover, the market caters to the needs of outpatient treatments, ensuring safety and effectiveness in the administration of injectable drugs. The geriatric population, a growing demographic, benefits greatly from these advancements, as they are more susceptible to chronic diseases and long-term therapies. Safety is a primary concern in the market, with a focus on reducing needle stick injuries and minimizing the risk of viral transmission.



This is especially important in the context of hospitals and healthcare facilities, where large volumes of injections are administered daily. The Asia Pacific markets represent a substantial growth opportunity for the market, driven by the increasing prevalence of long-term diseases and the need for injectable development in this region. The market is expected to witness steady growth, fueled by advancements in drug delivery technology and the increasing demand for vaccines and chronic disease management. In conclusion, the market plays a vital role in addressing the vaccination needs and long-term disease management requirements of healthcare systems. Its significance is underscored by the increasing prevalence of chronic diseases and the need for effective and safe drug delivery technology. The market's continued growth is expected to contribute positively to the healthcare industry, ensuring the availability of essential vaccines and injectable drugs for the global population.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Hospitals and clinics
  Home care
  Others


Product

  Syringe
  Needle


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By End-user Insights

The hospitals and clinics segment is estimated to witness significant growth during the forecast period.

In the healthcare sector, syringes and needles, specifically Ophthalmic Syringes, Bone Marrow Syringes, and Catheter Syringes play a significant role in various applications. Hospitals and clinics are the primary consumers of these healthcare products due to their essential use in administering medications, including vaccines, anticoagulants, and biologics. The benefits of using syringes and needles for drug delivery are numerous. They ensure ease of administration, precise dosing, and extended storage time, making them a preferred choice for healthcare professionals. The European Board of Anaesthesiology (EBA), the National Patient Safety Agency, and the Association of Anaesthetists of Great Britain and Ireland advocate for the use of syringes and needles in all possible applications.

Furthermore, disposable syringes and reusable syringes are both widely used in the healthca

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. NeisVac-C (Meningococcal Serogroup C-TT Conjugate Vaccine, Adsorbed) is the brand name for Baxter’s MenC conjugate vaccine sold in the EU and Australia. First approved in the UK in 2000, NeisVac-C is one of the first meningococcal conjugate vaccines to be used in active immunization against meningococcal meningitis, specifically MenC. Read More

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Menjugate (Meningococcal Group C -CRM197 Conjugate Vaccine) is the brand name for Novartis’ MenC conjugate vaccine registered in the EU, Australia, and Brazil. The vaccine was originally developed and marketed by Wyeth (now Pfizer), and Nuron Biotech acquired Meningitec in December 2012. Read More

Snapshot img

Animal Biotechnology Market Size 2025-2029

The animal biotechnology market size is forecast to increase by USD 4.47 billion at a CAGR of 3.3% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing strategies of market players to expand their product portfolios and geographical reach. This trend is particularly evident in the development of innovative solutions for animal health and productivity. However, the market also faces challenges, including the increasing prevalence of animal diseases, which necessitate the need for more accurate and timely diagnostic tests. This presents an opportunity for companies to invest in research and development of advanced diagnostic tools and services. Despite this potential, the market growth is hindered by the lack of a skilled workforce capable of performing complex diagnostic tests. This labor shortage can be addressed through collaborations between academia, industry, and governments to train and educate the next generation of animal biotechnology professionals. Companies seeking to capitalize on market opportunities and navigate challenges effectively should focus on building a strong workforce, investing in research and development, and collaborating with industry partners to stay ahead of the competition. By doing so, they will be well-positioned to meet the growing demand for animal health solutions and contribute to the overall growth of the market.

What will be the Size of the Animal Biotechnology Market during the forecast period?

Request Free SampleThe market encompasses a range of applications, including genetic engineering for enhancing animal productivity, reproductive technologies, and the development of animal-based goods and derived products. This sector is driven by the growing demand for animal health solutions, as well as the potential for animal biotechnology in cancer treatment and pharmaceutical development. Public health systems and the animal feed sector also benefit from biotech solutions, such as disease resistance, therapeutic proteins, and diagnostic tests. Molecular biology plays a crucial role in advancing animal health through the identification and prevention of zoonotic diseases and the development of vaccines and drug treatments. Additionally, animal welfare and health management are key areas of focus, with biotech products and cloning techniques contributing to preventative care and protein synthesis. Overall, the market is experiencing significant growth, with ongoing research and innovation in areas such as disease treatment, vaccine development, and animal agriculture efficiency.

How is this Animal Biotechnology Industry segmented?

The animal biotechnology industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. ProductDrugsVaccinesDiagnostic testsOthersAnimal TypeLivestock/productionCompanionTechnologyCRISPR-Cas9Gene transferGenome editingRNA interferenceNanotechnologyProduct TypeCloning servicesEmbryo biotechnologyGene editingIn vitro fertilization (IVF)Marker assisted selection (MAS)GeographyNorth AmericaUSCanadaEuropeFranceGermanyUKAsiaRest of World (ROW)

By Product Insights

The drugs segment is estimated to witness significant growth during the forecast period.Animal biotechnology encompasses various applications, including genetic composition, genetic engineering, reproductive technologies, animal health, animal-based goods, and animal-derived products. Genetic modification through techniques like electroporation method and random genomic integration is used to create genetically engineered animals with better nutritional profiles, disease resistance, and improved immunological responses. In vitro fertilization and genomic analytic tools are employed in clinical settings for genetic resources and diagnostics tests. Animal agriculture efficiency is enhanced through selective breeding and molecular biology, leading to improvements in cattle health, disease resistance, and the production of animal protein. Animal feed sector relies on feed additives and diagnostics tests for disease prevention and monitoring. Veterinary laboratories and point-of-care testing facilitate quick and accurate diagnosis of animal diseases, such as zoonotic diseases like foot and mouth disease (FMD), salmonella, swine fever, avian influenza, and bovine respiratory disease (BRD). Genetically modified organisms, including genetically altered transgenic animals, are used for cancer treatment, public health systems, and drug development. The use of these technologies in animal health and agriculture is crucial for maintaining animal welfare and ensuring food security.

Get a glance at the market report of share of various segments Request Free Sample

The Drugs seg